HER2-specific pseudomonas exotoxin a pe25 based fusions : Influence of targeting domain on target binding, toxicity, and in vivo biodistribution
The human epidermal growth factor receptor 2 (HER2) is a clinically validated target for cancer therapy, and targeted therapies are often used in regimens for patients with a high HER2 expression level. Despite the success of current drugs, a number of patients succumb to their disease, which motivates development of novel drugs with other modes of action. We have previously shown that an albumin
